RP 48497
(Synonyms: 右旋佐匹克隆杂质C) 目录号 : GC61253RP48497,是Eszopiclone的一种杂质,也是Eszopiclone的光降解产物。Eszopiclone是一种非苯二氮类镇静催眠药,用于失眠的研究。
Cas No.:148891-53-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
RP 48497, an impurity of Eszopiclone, is a photodegradation product of Eszopiclone. Eszopiclone is a non-benzodiazepine sedative-hypnotic used in the treatment of insomnia[1].
RP 48497 is a non-chiral potential photodegradation product whose formation is caused by bright light[1].
[1]. Sha Y, et al. Synthesis of RP 48497, an impurity of eszopiclone. Molecules. 2008 Aug 22;13(8):1817-21.
Cas No. | 148891-53-6 | SDF | |
别名 | 右旋佐匹克隆杂质C | ||
Canonical SMILES | O=C1N(C2=NC=C(Cl)C=C2)CC3=NC=CN=C31 | ||
分子式 | C11H7ClN4O | 分子量 | 246.65 |
溶解度 | 储存条件 | Store at -20°C | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.0543 mL | 20.2716 mL | 40.5433 mL |
5 mM | 0.8109 mL | 4.0543 mL | 8.1087 mL |
10 mM | 0.4054 mL | 2.0272 mL | 4.0543 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Synthesis of RP 48497, an impurity of eszopiclone
Molecules 2008 Aug 22;13(8):1817-21.PMID:18794786DOI:PMC6245065
RP 48497 is a photodegradation product of eszopiclone, a non-benzodiazepine sedative-hypnotic used in the treatment of insomnia. We report herein the first synthesis of RP 48497 via reduction, chlorination, and recyclization of 6-(5-chloropyridin-2-yl)-7-hydroxy-6,7-dihydropyrrolo[3,4-b]pyrazin-5-one (3), a key intermediate in the synthesis of eszopiclone. The structure of RP 48497 was confirmed by its (1)H-NMR and MS data. The mechanism of the reduction step in the synthesis of RP 48497 was also studied and the key parameters were determined. These findings should be important for quality control purposes in the manufacture of eszopiclone.